Process for preparing cephalosporins and intermediates therefor

Abstract: The invention relates to activated aminothiazolyl-oximinoacetic acid derivatives, their production and their use in the production of e.g. amides, in particular cephalosporin antiobiotics.

Description: This invention relates to 2-(2-aminothiazol-4-yl)-2-oxyimino-acetyl-sulphite-dialkylformimium halide hydrohalides of formula I in which X is halogen Y is alkyl of 1 to 4 carbon atom and Z is hydrogen, alkyl, phenalkyl, carbalkoxyalkyl, acyl or carboxyalkyl. The invention also relates to a process for the production thereof as well as to a process for the use thereof in the production of amides, in particular cephalosporins. The importance of amides of formula V, in which Z is as defined above and R₁ is the structural residue of an amine, usually obtained from amines of formula IV, R₁-NH₂ (IV) in which R₁ is as defined above, is known. A class of the amides of formula V which is of enormous interest are those produced from amines of formula IV which are 7-aminocephalosporanic acids. Such products are important cephalosporin antibiotics and include cefotaxime; ceftriaxone: cefmenoxime: ceftizoxime: and ceftazidime: cefetamet, cefuzoname, and desacetylcefotaxime, as well as corresponding monobactam antibiotics in which the amino group is attached to one ring of the β-lactam nucleus. The preparation of Formula V compounds has been widely described and covered in numerous patents. A large majority of such patents deal with the preparation of compounds having an antibiotic activity. The possibilities mentioned in the technical literature are, obviously, numerous. Without claiming to be exhaustive, certain cases reported to lead to good results may be cited. For example, the pathway leading to cefotaxime (sodium salt): Another known pathway of synthesis is similar to the above, except that the protection of the amino group is effected by triphenylmethylation, instead of by chloroacetylation, Spanish patents n o s 457.751 (Takeda), 469.116 and 457.115 (Roussel-Uclaf). Analytical Profiles (Vol. 11, pp 139-169, Academic Press (1982)) states that the synthesis used for the preparation of cefotaxime is as follows: EP 0023453 discloses a process for the production of cephalosporins in which 2-(2-aminothiazol-4-yl)-2-methoxyimino acetic acid is activated using tosyl chloride. Water soluble solvents are used and an excess of the activated 2-(2-aminothiazol-4-yl)-2-methoxy amino acetic acid is used. EP 00162395 discloses a process for the production of cephalosporins in which methanesulphonyl chloride is used to activate 2-(2-aminothiazol-4-yl)-2-methoxyamino acetic acid. Water soluble solvents are used in the production of the activated 2-(2-aminothiazol-4-yl)-2-methoxy amino acetic acid. Also an excess of the activated 2-(2-aminothiazol-4-yl)-2-methoxy amino acetic acid is required. EP 0226093 discloses a process for the production of cefodizime in which toluene sulphonyl chloride is used to activate 2-(2-amino-thiazol-4-yl)-2-methoxy amino acetic acid. A water soluble solvent is used and an excess of the activated 2-(2-aminothiazol-4-yl)-2-methoxy amino acetic acid is required. It is an object of the invention to provide a process not subject to the above complexities. In accordance with the invention, compounds of formula I are produced by a process comprising reacting a dialkylformiminium halide halosulfite of formula II: in which X and Y are as defined above, with 2-(2-aminothiazol-4-yl)-2-oxyiminoacetic acid of formula III in which Z is as defined above, to provide a solution or suspension of the compound of formula I. The reaction is conducted at temperatures lying between +5° and -60°C and it is, furthermore, preferred to use the syn isomer of the 2-(2-aminothiazol-4-yl)-2-oxyimino acetic acid which participates in the reaction. The use of the compounds of formula I in the preparation of amides comprises reacting said formula I compound with an anime of formula IV R₁ - NH₂ (IV) where R₁ is as defined above and is preferably selected from the group formed by: C₁-C₁₀alkyl, aryl, arylalkyl, alkenyl, a heterocyclic radical with one to three atoms of nitrogen or nitrogen and sulfur, an arylheterocyclic radical and a system of cendensed heterocylces, said reaction preferably being conducted in presence of a hydrogen chloride acceptor, to give a comopund of formula V where R₁ and Z are as hereinbefore defined. The process is of greatest interest when the formula IV compound is a 7-aminocephalosporanic acid of formula VI where R₃ is selected from the group formed by: -H; -CH₃; -CH₂Cl; -CH₂Br; -CH₂OCOCH₃; -Cl; -CH₂-OCONH₂; -O-CH₃; -CH=CH₂; -CH₂OH and -CH₂-R₄, where R₄ is a group which may be introduced by nucleophilic substitution in the acetoxy group of -CH₂-OCOCH₃, or a salt or protected form of said compound of formula VI. The said hydrogen chloride acceptor is preferably a tertiary nitrogen compound and more particularly a C₁₋₁₆ tertiary or heterocyclic amine, such as a pyridine or quinoline. The present invention allows the activation of the formula III acid "in situ" without costly blocking and unblocking operations of the amino group and without the need of intermediate isolations which involve complex purification steps. The preferred compound of formula II is dimethylformiminium chloride-chlorosulfite (D.F.C.S.) described in prior patents to the same applicant (Spanish patents 361743, 367136, 369916, and 403523) for activation of the formula III acid. The compound of formula II is easily prepared by reacting approximately equimolar amounts of thionyl chloride and dimethylformamide at room temperature in an appropriate solvent. When the solvent is of the benzene or toluene type, after the mixing stage the formula II compound separates out and is quickly decanted. Further reference will be made this fact hereinafter, in view of the importance it confers on the formula III acid activation step. Dropwise addition of the formula II compound to, preferably, a suspension of formula III acid, suitably in an organic solvent, and at a low temperature leads to the activation thereof in such a way that an amine may be added to prepare the corresponding amide with excellent yield, without the need for subsequent deblocking and costly purification stages. This synthesis pathway is extraordinarily simple in comparison with those currently being used and represents a notable advance in the preparation of third generation cephalosporin antibiotics. In fact, compare the normally used pathway: With the pathway of the invention: In many cases, the process of the invention saves the synthesis, as well as corresponding isolation and purification operations. The activation of the formula III acid is conducted via the formation of a mixed, sulfuric carboxylic, anhydride, of formula I. One important point is that it is important for the compound of formula II to conserve the sulfonic residue. In fact, if the formula II reactant is subjected to rather drastic conditions, the release of SO₂ occurs, with formation of a Vilsmeier's reagent as follows: This Vilsmeier's reagent has been used by the authors with very bad results in comparison with those obtained with the formula II reactant in good agreement with the disclosure of the Fujisawa patent (ES 457191); in Example 13 of this patent the Vilsmeier's reagent is prepared from phosphorus oxychloride and dimethylformamide in the presence of a silylating agent, using large excesses or reactants over the stoichiometrically required amounts. After an extremely complex isolation technique (associated with the lack of selectivity of the reaction), cefotaxime is isolated with a low yield. Poor results have also been obtained when attempts have been made to form the formula II reactant in solvents in which it did not separate out in its characteristic form of insoluble oil. Such in the case with methylene chloride and chloroform. The explanation is that the polarity of these solvents does not allow the formation of the Formula II reactant or facilitates its complete or partial conversion to the abovementioned Vilsmeier's reagent. As a result of problems encountered in producing the Formula V compounds, it has been conventional to use Formula III acid derivatives in which the amino group is blocked. Thus, compounds such as and others are obtainable on the market. The extremely simple and surprising activation process of the invention has been particularly studied with preferred "syn" isomeric form of the Formula III acid and with different 7-aminocephalosporanic acids to prepare cephalosporins of great therapeutical interest, such as cefotaxime, cefatriaxone and others mentioned above. A particularly appropriate form of dissolving the formula VI compounds for subsequent reaction is to form silyl derivatives using well known techniques. In this manner, the carboxyl group is silylated, e.g. trimethylsilylated, and the amino group of the compound VI may be similarly silylated, partially or completely. For a satisfactory reaction to be obtained, it is preferred to use a basic compound as acceptor of the hydrogen halide released during the acylation. Particularly appropriate basic compounds are tertiary amines such as dimethylaniline, pyridine,quinoline, undecylpyridine,triethylamine,tributylamineand others. The compound II is suitably formed in solvents in which , owing to its apolar nature, it separates out as an insoluble oil in a practically quantitative amount. Toluene has been considered to be particularly appropriate. Once the formula II reactant has been formed, it is suitably poured dropwise over a suspension or solution of the formula III acid in an anhydrous medium. The ideal temperature for activating the formula III acid lies between +5° and - 60°C. Higher temperatures produce reductions in yield in the acylation step, due possibly to total or partial decomposition of the formula II or I compounds with release of SO₂. The same temperature range is appropriate for the acylation step. The acylation reaction is preferably conducted in an anhydrous medium which may be provided, for example, by an organochlorinated solvent without excluding others used frequently in the chemical and pharmaceutical industry. The use of conventional silylating agents such as hexamethyldisilazane, bisilylacetamide, bisilylurea, trimethylchlorosilane and others, used alone or in mixture in proportions not precluding the partial or total silylation of the amino group is considered to be appropriate for silylation of formula VI compounds. Salts of the formula VI compound may be employed instead of silylated derivatives, but this is less preferred. Esters other than silyl esters of the formula VI compound, such as benzhydryl, trityl, etc. esters may also be used. Since the formula V compounds are aminoacids, they may be isolated as such or as pharmaceutically acceptable salts. To summarize, the best results in the preparation of formula V compounds are obtained when the formula I intermediate is formed at low temperature and is thereafter reacted with a 7-aminocephalosporanic acid dissolved in silyl ester form, with the totally or partially silylated amino group in the presence of an acceptor base, without subsequent treatment. In the compounds of formula I and II, X is preferably chlorine and Y is preferably methyl. In the compounds of formula I, III and V, Z is preferably alkyl, more preferably C₁₋₄ alkyl, most preferably methyl. It may alternatively be hydrogen; phenalkyl, preferably phen (C₁₋₄) alkyl; carbalkoxyalkyl, e.g. carb (C₁₋₄) alkoxy (C₁₋₄)alkyl, e.g. -C(CH₃)₂COO t -butyl or CH₂-COOt-butyl; acyl, e.g. C₂₋₅ alkanoyl; or carboxyalkyl e.g. carboxymethyl or -C(CH₃)₂COOH. The preferred compounds of formula V are in syn isomeric form and are preferably of formula Va in which Z and R₃ are as defined above. R ₃ may have any of the significances set forth above but is preferably hydrogen methyl, acetoxy methyl, -O―CH₃;-CH=CH₂;-CH₂OH and -CH₂-R₄ or pyridiniummethyl. The use of the compounds of formula I of the invention on producing amides of formula V has been described above. The compounds of formula I may also be used for the production of other products such as esters by reaction with suitable alcohols. There are described hereinafter examples of the invention. EXAMPLE 1 7((2-2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido)cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA). 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene; the mixture turned turbid almost immediately and an oil separated out, which was decanted in the lower portion (dimethylformiminium chloride chlorosulfite-DFCS). The DFCS was added dropwise over 5 minutes to a suspension of 2.21 g of ATMAA in 13 ml of CH₂Cl₂, previously chilled to 0/5°C, followed by stirring for 30 minutes at 0/5°C to give a yellow solution from 2 minutes onwards. This solution, chilled to -40/-45°C formed preparation A. B) 7-aminocephalosporanic acid (7-ACA) solution. 13 ml of CH₂Cl₂ were mixed with 2.72 g of 7-ACA and 2.1 ml of hexamethyldisilazane, followed by heating to reflux for two hours with energetic stirring. After 50 minutes approximately a solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -50/-55°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -35°C. After 5 minutes stirring, the reaction was considered as terminated, although the acylation time may be extended, without negative influences. Synthesis control by liquid chromatography (HPLC) showed the formation of the title product (Cefotaxime) with a yield lying between 90/95% depending on the potency of the starting product (7-ACA). Cefotaxime may be isolated from the crude reaction product in acid or salt form. EXAMPLE 2 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1, but replacing the dimethylaniline in paragraph B with 5 ml of N,N-methyldodecylaniline, cefotaxime was prepared with a similar yield. EXAMPLE 3 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido)-cephalosporanic acid (Cefotaxime) Following Example 1, but replacing the dimethylaniline in paragraph B with 1.9 ml of quinoline, cefotaxime was prepared with an 80/85% yield. EXAMPLE 4 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1, but replacing the dimethylaniline in paragraph B with 2.23 ml of triethylamine, cefotaxime was prepared with an 80/85% yield. EXAMPLE 5 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1, but replacing the dimethylaniline of paragraph B with 1.56 ml of alpha-picoline, cefotaxime was prepared with an 83/88% yield. EXAMPLE 6 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1, but replacing the dimethylaniline of paragraph B with 1.29 ml of pyridine, cefotaxime was prepared with a 74/79% yield. EXAMPLE 7 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido)cephalosporanic acid (Cefotaxime) Following Example 1, but missing out the dimethylaniline of paragraph B and not using any acceptor base. In this case, the synthesis control by liquid chromatography (HPLC) revealed the formation of approximately 65% of cefotaxime, while approximately 30% of the 7-ACA remains unreacted. EXAMPLE 8 7(2-2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA). 0.94 ml of dimethylformamide and 0.87 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene. The dimethylformiminium chloride chlorosulfite (DFCS) was decanted as an insoluble oil from the lower phase. The DFCS was added dropwise over 15 minutes to a suspension of 2.21 g of ATMAA in 13 ml of CH₂Cl₂, previously chilled to 0/5°C, without obtaining a total solution in this case. The solution was chilled to -20/-25°C, forming preparation A. B) 7-aminocephalosporanic acid (7-ACA) solution. 13 ml of CH₂Cl₂ were mixed with 2.72 g of 7-ACA and 2.1 ml of hexamethyldisalazane, followed by heating to reflux for two hours with energetic stirring. As from 50 minutes approximately a solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -20/-25°C. This solution formed preparation B. C) Acylation Preparation A was poured dropwise over preparation B as quickly as possible, without the temperature rising above -15°C. After 10 minutes stirring at -15/-20°C, a complete solution was observed. Chromatographic control by HPLC showed a cefotaxime yield of 74/79%. EXAMPLE 9 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 8, but replacing the 6 ml of toluene of paragraph B with 6 ml of benzene, similar results were obtained. EXAMPLE 10 7(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA). 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene; the mixture turned turbid almost immediately and an oil separated out, which was decanted in the lower portion (DFCS). The DFCS was added dropwise over 2 minutes to a suspension of 2.21 g of ATMAA in 13 ml of CH₂Cl₂, previously chilled to 0/5°C, followed by stirring for 25 minutes at 0/5°C, a solution being obtained almost immediately. This solution, chilled to -40/-45°C formed preparation A. B) 7-aminocephalosporanic acid (7-ACA) solution. 13 ml of CH₂Cl₂ were mixed with 2.72 g of 7-ACA and 3.5 ml of bisilylacetamide and was stirred for two hours. As from 90 minutes a complete solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -50/-55°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -30°C. After 15 minutes, the reaction was considered as terminated. Liquid chromatography (HPLC) showed the formation of cefotaxime with a yield lying between 88/92%. EXAMPLE 11 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 10, but replacing the bisilylacetamide of paragraph B with 2.92 g of bisilylurea, cefotaxime was obtained with a similar yield. EXAMPLE 12 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1 but refluxing for 15 minutes after stirring for 30 minutes at 0/5°C in paragraph A. The cefotaxime yield lies between 35/40% EXAMPLE 13 7(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cefalosporanic acid (Cefotaxime) Following Example 1 but modifying the temperature for the 30 minutes stirring in paragraph A to 20/25°C. The cefotaxime yield lies between 75/80% EXAMPLE 14 7(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA) 13 ml of CH₂Cl₂ were chilled to 0/5°C and 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added, with a complete solution being obtained. The solution was chilled to -5°C and 2.21 g of ATMAA were added. After 30 minutes an orange coloured solution was obtained. B) 7-aminocephalosporanic acid (7-ACA) solution. 13 ml of CH₂Cl₂ were mixed with 2.72 g of 7-ACA and 2.1 ml of hexamethyldisilazane and was heated to reflux for 2 hours with vigorous stirring. As from 50 minutes approximately a solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -50/-55°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -35°C. After 5 minutes stirring, the reaction was considered as terminated, although the acylation time may be extended without negative influences. Control of synthesis by liquid chromatography (HPLC) showed the formation of the title product (Cefotaxime) with a yield lying between 25/30% depending on the potency of the starting product (7-ACA). Note: Following this Example, but deleting the dimethylformamide, i.e. using only thionyl chloride, no formation of cefotaxime is detected by liquid chromatography (HPLC). EXAMPLE 15 7(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA). 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene; the mixture turned turbid almost immediately and an oil separated out, which was decanted in the lower portion (dimethylformiminium chloride chlorosulfite) (DFCS). The DFCS was added dropwise over 5 minutes to a suspension of 2.21 g of ATMAA in 13 ml of CH₂Cl₂, previously chilled to 0/5°C, followed by stirring for 30 minutes at 0/5°C to give a yellow solution from 2 minutes onwards. This solution, chilled to -40/-45°C formed preparation A. B) 7-aminocephalosporanic acid (7-ACA) solution. 2.72 g of 7-ACA were suspended in 14 ml of methylene chloride and the suspension was chilled to 10°C. 1.25 ml of tetramethylguanidine were added, followed by stirring for 15 minutes at 15/20°C. A yellow-ochre solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -25/-30°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -20°C. After 1 hour stirring at -20/-25°C, chromatography (HPLC) showed a cefotaxime yield lying between 23/27%. EXAMPLE 16 7(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid . (Cefotaxime) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA) 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene; the mixture turned turbid almost immediately and an oil separated out, which was decanted in the lower portion (DFCS). The D.F.C.S. was added dropwise over 5 minutes to 13 ml of CH₂Cl₂, previously chilled to 0/5°C follow by stirring for 15 minutes with a complete solution being obtained at 0/5 º C. 2.21 g of ATMAA were added followed by stirring for 25 minutes at 0/5 º C. An orange coloured solution was obtained. B) 7-aminocephalosporanic acid (7-ACA) solution. 13 ml of CH₂Cl₂ were mixed with 2.72 g of 7-ACA and 2.1 ml of hexamethyldisilazane and was heated to reflux for 2 hours with vigorous stirring. As from 50 minutes approximately a solution was obtained. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by cooling to -50/-55°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -35°C. After 5 minutes stirring, the reaction was considered as terminated, although the acylation time may be extended without negative influences. Control of synthesis by liquid chromatography (HPLC) showed the formation of the title product (Cefotaxime) with a yield lying between 25/30% depending on the potency of the starting product (7-ACA). EXAMPLE 17 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Examople 1 but amending the acylation step. C) Acylation Preparation B was poured over preparation A, over a period of 2 minutes, without the temperature exceeding -35°C. The formation yield of cefotaxime was between 50/55%. EXAMPLE 18 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) cephalosporanic acid (Cefotaxime) Following Example 1 but amending the acylation technique C. C) Acylation Preparation A was poured over preparation B as quickly as possible while ensuring that the temperature did not rise above -45°C. After 30 minutes reaction at -40/45 º C, 30 ml of methylene chloride were added, allowing the temperature to rise to -15°C, then 15 ml of water were added and after 5 minutes stirring at 20/25 º C, the lower organic phase was decanted and the process was continued with the aqueous phase, to which 10 ml of acetone were added. The pH was adjusted to 2.1 by addition of NaOH (4N) at 20/25°C. A solid precipitated out after a few instants; after stirring for 5 minutes, the pH was adjusted to 3.0 and stirring was continued for 60 minutes at 0/5°C. The product was filtered, washed with 15 ml of aqueous acetone (50%, v/v) to give 4.0 g of cefotaxime (yield 88%). EXAMPLE 19 7(((2-aminothiazol-4-yl)(methoxyimino)-acetyl)amino)-8-oxo-3(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo (4.2.0) oct-2-ene-2-carboxylic acid . (Ceftriaxone) A) Activation of the 2-(2-aminothiazol-4-yl)-2-syn-methoxyimino acetic acid (ATMAA) 1.24 ml of dimethylformamide and 1.15 ml of thionyl chloride were added to a compensated pressure funnel containing 6 ml of toluene; the mixture turned turbid almost immediately and an oil separated out, which was decanted in the lower portion (dimethylformiminium chloride chlorosulfite) (DFCS). The DFCS was added dropwise over 5 minutes to a suspension of 2.21 g of ATMAA in 13 ml of CH₂Cl₂, previously chilled to 0/5°C, followed by stirring for 30 minutes at 0/5°C to give a yellow solution from 2 minutes onwards. This solution, chilled to -40/-45°C formed preparation A. B) 7-amino-3-desacetoxy-3-((2,5-dihydro-6-hydroxy-2-methyl-5-oxo-as-triazin-3-yl)thio)cephalosporanic acid (7-ADTC) solution. 15 ml of CH₂Cl₂, 3.71 g of 7-ADTC, 4,53 ml of hexamethyldisilazane and 0.07 g of imidazole were mixed together, with heating for two hours, giving a complete solution. The solution was chilled to 10°C and 2.0 ml of dimethylaniline were added, followed by final cooling to -30/-35°C. This solution formed preparation B. C) Acylation Preparation A was poured over preparation B as quickly as possible, without the temperature rising above -30°C. After 30 minutes stirring at -30/-25°C, liquid chromatography (HPLC) control showed the formation of the title product (Cefatriaxone) with a yield of 80%. The cefatriaxone may be isolated from the crude reaction product in acid or salt form. EXAMPLE 20 7(((2-aminothiazol-4-yl)(methoxyimino)-acetyl)amino)-8-oxo-3(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo (4.2.0) oct-2-ene-2-carboxylic acid. (Ceftriaxone) Following Example 19, but modifying the 7-ADTC solution stage (Paragraph B). 50 ml of CH₂Cl₂, 8 ml of bisilylacetamide and 3.71 g of 7-ADTC were mixed together; the mixture was stirred for 3 hours at 20/25°C to give a complete solution. The yield in this case was 83% EXAMPLE 21: 7(((2-aminothiazol-4-yl)(methoxyimino)-acetyl)amino)-8-oxo-3(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo (4.2.0) oct-2-ene-2-carboxylic acid. (Ceftriaxone) Following example 19 but replacing the 2.0 ml of dimethylaniline in paragraph B with 5.0 ml of N,N-methyldodecylaniline. The yield is this case was 81%. EXAMPLE 22: 7(((2-aminothiazol-4-yl)(methoxyimino)-acetyl)amino)-8-oxo-3(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo (1.2.0) oct-2-ene-2-carboxylic acid. (Ceftriaxone) Following example 19 but the acylation (paragraph C) was carried out at - 15/-20°C. The yield in this case was 76%. EXAMPLE 23: The following compounds were prepared with 70% to 96% yields, under similar conditions to those listed in examples 1 to 22, using dimethylformiminium chloride chlorosulfite (DFCS) for the activation of the 2-(2-aminothiazol-4-yl)-2-methoxyimino acetic acid (ATMAA); and reacting the activated form of the ATMAA with an appropriate primary amine of formula R₁-NH₂ in methylene chloride at a temperature lying between -55/-10°C in the presence of an acceptor base selected from the groups formed by dimethylaniline, pyridine, methyldodecylaniline, alphapicoline, quinoline and triethylamine. 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminacetamido)desacetoxycephalosporanic acid (CEFETAMET). 7-(((2-aminothiazol-4-yl)(syn-methoxyimino)acetyl)amino-3-(((1-methyl-1H-tetrazol-5-yl)thio) methyl)-8-oxo-5-thia-1-azabicyclo-(4.2.0)oct-2-ene-2-carboxylic acid (CEFMENOXIME) 7-(((2-aminothiazol-4-yl)(syn-methoxyimino)acetyl)amino-8-oxo-5-thia-1-azabicyclo (4.2.0) oct-ene-2-carboxylic acid (CEFTIZOXIME) 7 beta-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido-3-((1,2,3-thiadiazol-5-yl)-3-cephem-4-carboxylic acid. (CEFUZONAME). 7-(2-(2-aminothiazol-4-yl)-2-syn-methoxyiminoacetamido) desacetoxycephalosporanic acid (DESACETYLCEFOTAXIME), (CEFTAZIDIME)

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A compound of formula I, in which X is halogen, Y is alkyl of 1 to 4 carbon atoms and Z is hydrogen, C₁₋₄ alkyl, phen-C₁₋₄-alkyl, carb-C₁₋₄-alkoxy-C₁₋₄-alkyl, C₂₋₅alkanoyl or carboxy-C₁₋₄-alkyl. A compound according to claim 1, which is 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl sulfite dimethylformiminium chloride hydrochloride. A compound of claim 1 or 2 in syn isomeric form. A process for the production of a compound of formula I, as defined in claim 1, comprising reacting dialkylformiminium halide halosulfite of formula II: in which X and Y are as defined in claim 1, with 2-(2-aminothiazol-4-yl)-2-oxyiminoacetic acid of formula III in which Z is as defined in claim 1, at a temperature in the range 5°C to - 60°C, to provide a solution or suspension of the compound of formula I, and if desired isolating the resulting compound of formula I. A process for the production of a compound of formula V, in which R₁ is the residue of an amine and Z is as defined in claim 1, comprising reacting a compound of formula I, stated in claim 1, with a compound of formula IV, R₁-NH₂ (IV) in which R₁ is as defined above. A process according to claim 5 in which the compound of formula IV is a compound of formula VI where R₃ is selected from: -H; -CH₃; -CH₂Cl; -CH₂Br; -CH₂OCOCH₃; -Cl; -CH₂-OCONH₂; -O-CH₃ ; -CH=CH₂; -CH₂OH and CH₂-R₄, where R₄ is a group which may be introduced by nucleophilic substitution in the acetoxy group of -CH₂-OCOCH₃, or a salt or protected from of said compound of formula VI. A process according to claim 5 or claim 6 in which the compound of the formula I is prepared by a process according to claim 4. The use of a compound of formula I, as defined in claim 1, in the production of cephalosporins. Claims for the following Contracting States : ES, GR A process for the production of compound of formula I, in which X is halogen, Y is alkyl of 1 to 4 carbon atoms and Z is hydrogen, C₁₋₄ alkyl, phen-C₁₋₄-alkyl, carb-C₁₋₄-alkoxy-C₁₋₄-alkyl, C₂₋₅alkanoyl or carboxy-C₁₋₄-alkyl, comprising reacting dialkylformiminium halide halosulfite of formula II: in which X and Y are as defined above, with 2-(2-aminothiazol-4-yl)-2-oxyiminoacetic acid of formula III in which Z is as defined above, at a temperature in the range 5°C to - 60°C, to provide a solution or suspension of the compound of formula I, and if desired isolating the resulting compound of formula I. A process according to claim 1 in which the compound of the formula I is 2-(2-aminothiazol-4-yl)-2-methoxyiminoacetyl sulfite dimethylformiminium chloride hydrochloride. A process according to claim 1 or claim 2 in which the compound of formula I is in syn isomeric form. A process for the production of a compound of formula V, in which R₁ is the residue of an amine and Z is as defined in claim 1, comprising reacting a compound of formula I, stated in claim 1, with a compound of formula IV, R₁-NH₂ (IV) in which R₁ is as defined above. A process according to claim 4 in which the compound of formula IV is a compound of formula VI where R₃ is selected from: -H; -CH₃; -CH₂Cl; -CH₂Br; -CH₂OCOCH₃; -Cl; -CH₂-OCONH₂; -O-CH₃ ;-CH=CH₂;-CH₂OH and CH₂-R₄ , where R₄ is a group which may be introduced by nucleophilic substitution in the acetoxy group of -CH₂-OCOCH₃, or a salt or protected from of said compound of formula VI. A process according to claim 4 or claim 5 in which the compound of the formula I is prepared by a process according to claim 1. The use of a compound of formula I, as defined in claim 1, in the production of cephalosporins.

Inventors: DIAGO MESEGUER JOSE, ESTEVE BIANCHINI ASUNCION, LENHARDT PADRO CARLOS E, SANS PITARCH ESTEVE, DIAGO MESEGUER, JOSE, ESTEVE BIANCHINI, ASUNCION, LENHARDT PADRO, CARLOS E., SANS PITARCH, ESTEVE
Applicants: BIOCHEMIE SA, BIOCHEMIE, S.A.
Application year: 1989
Main classification: C07D277
IPC codes: C07D501, A61K31, C07D277, A61P31